Shanghai, China, 08 December 2021 — An article depicting the real-world use of the Castor™ Branched Aortic Stent-Graft System (Castor™), developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), has been published in internationally-renowned medical journal Endovascular Today (EVT). The article, co-authored by eight specialists from China, Italy, Poland, and Brazil, is a compilation of four clinical use cases of Castor™.
As a leading medical journal, EVT provides comprehensive coverage of all new technologies and developments in the endovascular field, aiming to share the latest clinical trial data and innovative medical products. EVT is published monthly with various feature-based column sections, such as carotid artery, venous, neurological, radiological, and cardiovascular diseases. Its editorial advisory board is composed of more than 90 top endovascular specialists from around the world, including interventional cardiologists, interventional radiologists, neurointerventionalists, and vascular medicine practitioners, who provide expert review on submitted articles.
Within the article, Prof. Qingsheng Lu and Prof. Xiaoye Li commented that Castor™, “showed a high technical success rate of 97% at the initial clinical use stage, with no endoleak observed during follow-ups and a low incidence of follow-up complications. By extending the proximal landing zone into lshimaru zone 2 and revascularizing the LSA, the Castor™ branched stent graft provides an effective and reliable endovascular option for TBAD with insufficient healthy aorta beyond the LSA or with LSA involvement.”1
Prof. Michele Antonello and Prof. Michele Piazza wrote, “Castor™ is the first branched stent graft specifically designed for the aortic arch,” adding that its unibody design allowed a single branch to extend into the LSA without the need for adjunctive surgical procedures.
The publishing of “Real-World Use of the Castor™ Branched Aortic Stent Graft System for Treatment of TBAD” in EVT shows that the efficacy of Castor™ Stent is widely recognized by industry leaders. In the future, Endovastec™ will continue to introduce more independently-developed premium medical devices to the global market, and will strive to benefit more patients with aortic and peripheral vascular diseases.
Castor™ Branched Aortic Stent-Graft System is the world’s first stent-graft system for simultaneous aorta and aortic arch repair through minimally invasive treatment. Its unique unibody structure can adapt to a variety of arch anatomies and allows one-off access and release, which ensures safe and convenient rebuilding of the left subclavian artery, whilst reducing incidence of endoleaks and providing long-term stability. Since its launch, the Castor™ stent has been used for 8,000 implantations and has entered more than 600 hospitals in China. It is now available in six overseas countries, and is widely recognized by clinical specialists for its innovative features.
1. Jing Z, Lu Q, Feng J, et al. Endovascular repair of aortic dissection involving the left subclavian artery by Castor stent graft: a multicentre prospective trial. Eur J Vasc Endovasc Surg. 2020;60:854-861. doi: 10.1016/j.ejvs.2020.08.022
For more information, see https://evtoday.com/articles/2021-nov/real-world-use-of-the-castor-branched-aortic-stent-graft-system-for-treatment-of-tbad